Esperion Therapeutics Company Profile (NASDAQ:ESPR)

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics logoEsperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ESPR
  • CUSIP: N/A
  • Web:
  • Market Cap: $741.63 million
  • Outstanding Shares: 22,590,000
Average Prices:
  • 50 Day Moving Avg: $36.15
  • 200 Day Moving Avg: $23.68
  • 52 Week Range: $9.40 - $48.21
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.53
  • P/E Growth: 0.87
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $8.52 per share
  • Price / Book: 3.85
  • EBIDTA: ($101,960,000.00)
  • Return on Equity: -21.76%
  • Return on Assets: -21.07%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 26.16%
  • Quick Ratio: 26.16%
  • Average Volume: 1.97 million shs.
  • Beta: 2.1
  • Short Ratio: 3.17

Frequently Asked Questions for Esperion Therapeutics (NASDAQ:ESPR)

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics Inc (NASDAQ:ESPR) posted its quarterly earnings results on Monday, May, 1st. The company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.36. During the same quarter in the previous year, the company earned ($0.65) EPS. View Esperion Therapeutics' Earnings History.

Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2017?

11 brokers have issued twelve-month price objectives for Esperion Therapeutics' stock. Their forecasts range from $12.50 to $67.00. On average, they expect Esperion Therapeutics' share price to reach $36.86 in the next twelve months. View Analyst Ratings for Esperion Therapeutics.

What are analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:

  • 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (5/9/2017)
  • 2. Needham & Company LLC analysts commented, "The FDA has agreed that the Phase III CLEAR LDL program of bempedoic acid is sufficient to support approval. This resolves a long standing issue for ESPR shares regarding the ability to get their drug approved without a completed CVOT. This regulatory confirmation comes on the heals of the positive FOURIER outcomes data for Repatha and the genetic validation of the target for bempedoic acid which was presented yesterday at the American College for Cardiology (ACC). As a result of this trifecta of positive news we are increasing our price target on ESPR to $58 from $25. We once again model US approval based on CLEAR LDL in 2020." (3/20/2017)

Who are some of Esperion Therapeutics' key competitors?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the folowing people:

  • Timothy M. Mayleben, President, Chief Executive Officer, Director
  • Narendra D. Lalwani Ph.D., FAHA, DABT, Chief Operating Officer, Executive Vice President - Research & Development
  • Mary P. McGowan M.D., Chief Medical Officer
  • Nicole Vitullo MBA, Independent Lead Director
  • Roger S. Newton Ph.D., FAHA, FACN, Director
  • Scott N. Braunstein M.D., Independent Director
  • Dov A. Goldstein M.D., Independent Director
  • Antonio M. Gotto Jr., M.D., Ph.D., Independent Director

Who owns Esperion Therapeutics stock?

Esperion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BOXER CAPITAL, LLC (6.80%), ALTA PARTNERS VIII, L.P. (6.50%), BB Biotech AG (6.24%), FMR LLC (5.80%), Boxer Capital LLC (5.64%) and Credit Suisse AG (3.89%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

Who sold Esperion Therapeutics stock? Who is selling Esperion Therapeutics stock?

Esperion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC, Bank of America Corp DE, Martingale Asset Management L P, JPMorgan Chase & Co., Cim Investment Mangement Inc., Bellevue Group AG, Keybank National Association OH and Oxford Asset Management. View Insider Buying and Selling for Esperion Therapeutics.

Who bought Esperion Therapeutics stock? Who is buying Esperion Therapeutics stock?

Esperion Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, RA Capital Management LLC, Pinnacle Associates Ltd., FMR LLC, Aviva Holdings Ltd., UBS Asset Management Americas Inc., Credit Suisse AG and State Street Corp. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.

How do I buy Esperion Therapeutics stock?

Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of Esperion Therapeutics stock can currently be purchased for approximately $32.83.

MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  432
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (?)
Ratings Breakdown: 6 Hold Ratings, 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $36.86 (12.29% upside)

Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/20/2017JPMorgan Chase & Co.Reiterated RatingHold$22.00 -> $50.00MediumView Rating Details
3/20/2017Citigroup IncSet Price TargetBuy$39.00MediumView Rating Details
3/20/2017Royal Bank of CanadaReiterated RatingHold$45.00HighView Rating Details
3/20/2017Needham & Company LLCBoost Price TargetStrong-Buy -> Strong-Buy$25.00 -> $58.00HighView Rating Details
3/20/2017Credit Suisse Group AGUpgradeUnderperform -> Neutral$29.00HighView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/15/2016Stifel NicolausReiterated RatingBuy$64.00 -> $30.00N/AView Rating Details
10/15/2016Chardan CapitalReiterated RatingNeutral$12.50N/AView Rating Details
8/31/2016Barclays PLCSet Price TargetHold$13.00N/AView Rating Details
7/5/2016WallachBeth CapitalDowngradeBuy -> Hold$35.00N/AView Rating Details
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 -> $27.00N/AView Rating Details
11/6/2015Bank of America CorpReiterated RatingBuy$65.00N/AView Rating Details
8/17/2015FIXReiterated RatingaddN/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Esperion Therapeutics (NASDAQ:ESPR)
Earnings by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Earnings History by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($1.44)($1.80)ViewN/AView Earnings Details
2/22/201712/31/2016($1.24)($1.29)ViewN/AView Earnings Details
11/3/2016Q3($0.82)($0.77)ViewN/AView Earnings Details
8/4/2016Q2($0.78)($0.62)ViewN/AView Earnings Details
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details
2/25/2016Q4($0.61)($0.58)ViewN/AView Earnings Details
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details
5/7/2015Q115($0.54)($0.56)ViewN/AView Earnings Details
3/5/2015Q4 2014($0.54)($0.49)ViewN/AView Earnings Details
8/12/2014Q214($0.55)($0.60)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.62)($0.51)ViewN/AView Earnings Details
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)
Current Year EPS Consensus Estimate: $-6.69 EPS
Next Year EPS Consensus Estimate: $-4.36 EPS


Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Esperion Therapeutics (NASDAQ:ESPR)
Insider Ownership Percentage: 35.40%
Institutional Ownership Percentage: 64.65%
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/22/2017Dov A Md GoldsteinDirectorSell800,000$41.66$33,328,000.00View SEC Filing  
3/21/2017Gilbert S OmennDirectorBuy1,000$42.26$42,260.00View SEC Filing  
11/1/2016Narendra D LalwaniCOOBuy5,000$9.93$49,650.00View SEC Filing  
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00View SEC Filing  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.00View SEC Filing  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.00View SEC Filing  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.00View SEC Filing  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.00View SEC Filing  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Esperion Therapeutics (NASDAQ:ESPR)
Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
DateHeadline logoEsperion Therapeutics Inc (ESPR) Receives Consensus Rating of "Buy" from Brokerages - May 22 at 2:17 PM logoEsperion Provides Update on Common Stock Trading Activity - May 22 at 11:42 AM logoEsperion Therapeutics: Up, Up, And Away? - Seeking Alpha - May 19 at 9:51 PM logoEsperion to Participate in Fireside Chat at the UBS Global Healthcare Conference - May 19 at 4:49 PM logoEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 19 at 5:19 AM logoEsperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference - May 12 at 5:34 PM logoEsperion Therapeutics Inc (ESPR) Rating Increased to Hold at Zacks Investment Research - May 9 at 7:30 PM logoToday's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics - May 8 at 9:08 AM logoWhy Esperion Therapeutics Shares Were Flat In April - May 6 at 10:37 AM logoEsperion Therapeutics reports 1Q loss - May 5 at 5:16 PM logoEsperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results - May 4 at 5:11 PM logoZacks: Analysts Anticipate Esperion Therapeutics Inc (ESPR) Will Announce Earnings of -$1.48 Per Share - May 4 at 1:26 PM logoEsperion Therapeutics (ESPR) Receiving Somewhat Positive Press Coverage, Analysis Finds - May 2 at 9:52 AM logoEsperion Therapeutics Inc (ESPR) Stock Rating Lowered by Zacks Investment Research - May 1 at 9:30 PM logoSomewhat Favorable Press Coverage Extremely Likely to Impact Esperion Therapeutics (ESPR) Stock Price - April 29 at 12:53 PM logoEsperion Therapeutics Inc (ESPR) to Release Earnings on Monday - April 29 at 7:09 AM logoEsperion Therapeutics (ESPR) Receives Daily Coverage Optimism Score of 0.20 - April 27 at 1:11 AM logoEsperion Therapeutics Inc (ESPR) Given Average Rating of "Buy" by Brokerages - April 25 at 2:50 PM logoEsperion Therapeutics (ESPR) Earns News Impact Rating of 0.15 - April 23 at 10:02 PM logoEsperion Therapeutics (ESPR) Getting Somewhat Favorable Press Coverage, AlphaOne Reports - April 20 at 9:47 PM logo3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich - April 19 at 12:13 PM logoSomewhat Positive News Coverage Very Likely to Affect Esperion Therapeutics (ESPR) Share Price - April 17 at 10:16 PM logoRoyal Bank of Canada Reaffirms Hold Rating for Esperion Therapeutics Inc (ESPR) - April 16 at 12:52 PM logoSomewhat Favorable Press Coverage Extremely Likely to Impact Esperion Therapeutics (ESPR) Share Price - April 14 at 9:09 PM logoZacks: Analysts Expect Esperion Therapeutics Inc (ESPR) to Announce -$1.48 EPS - April 13 at 11:22 AM logoCardiovascular Players Could Be Eyeing Esperion - April 11 at 4:53 PM logoRegeneron's Evinacumab Gets Breakthrough Designation (REGN) - April 7 at 9:42 AM logoThe 3 Best Cholesterol Drug Stocks to Buy in 2017 - March 30 at 5:30 PM logoEsperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference - March 28 at 4:44 PM logoJPMorgan Chase & Co. Increases Esperion Therapeutics Inc (ESPR) Price Target to $50.00 - March 27 at 10:25 AM logoCitigroup Inc Raises Esperion Therapeutics Inc (ESPR) Price Target to $77.00 - March 25 at 9:33 AM logoDov A. Md Goldstein Sells 800,000 Shares of Esperion Therapeutics Inc (ESPR) Stock - March 23 at 7:35 PM logoInsider Buying: Esperion Therapeutics Inc (ESPR) Director Purchases 1,000 Shares of Stock - March 22 at 10:52 AM logoEsperion Therapeutics Inc (ESPR) Given a $39.00 Price Target by Citigroup Inc Analysts - March 21 at 4:25 PM logoEsperion Therapeutics' (ESPR) Hold Rating Reaffirmed at JPMorgan Chase & Co. - March 21 at 3:03 PM logoEsperion Therapeutics Inc (ESPR) Price Target Raised to $50.00 at JPMorgan Chase & Co. - March 21 at 11:34 AM logoEsperion Gets FDA Nod for LDL-C Program (ESPR) - March 20 at 7:34 PM logoEsperion Therapeutics upgraded by Credit Suisse - March 20 at 7:34 PM logoEsperion Therapeutics stock surges 52% after it says the FDA gave its drug program positive feedback - March 20 at 7:34 PM logoEsperion Gets FDA Nod for Cholesterol Drug Program - March 20 at 7:34 PM logoHere's What Pushed Esperion Therapeutics Inc Stock Higher Today - March 20 at 7:34 PM logoAfter-hours buzz: ESPR, NKTR, MMSI & more - March 20 at 7:34 PM logoRoyal Bank of Canada Reiterates Hold Rating for Esperion Therapeutics Inc (ESPR) - March 20 at 4:24 PM logoEsperion Therapeutics Inc (ESPR) PT Raised to $58.00 - March 20 at 1:43 PM logoEsperion Therapeutics Inc (ESPR) Raised to "Neutral" at Credit Suisse Group AG - March 20 at 12:16 PM logoHere's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today - Motley Fool - March 18 at 10:16 AM logoEsperion Falls Victim To Amgen's Poor Repatha Results - March 17 at 10:24 PM logoAmgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble - March 17 at 5:23 PM logoEsperion Therapeutics Inc (ESPR) PT Set at $39.00 by Citigroup Inc - March 13 at 4:28 PM logoEsperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6% - Nasdaq - March 10 at 6:09 PM



Esperion Therapeutics (ESPR) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff